Thrombopoietin (TPO) is the physiologic Mpl-ligand regulating platelet production. Pegylated human recombinant megakaryocyte growth and development factor (PEGrHuMGDF), a truncated polypeptide Mpl-ligand derivitized with poly4ethylene glycol), induces megakaryocyte endoreduplication and proliferation in vitro and in vivo. In the present study, the dose-response effects of PEG-rHuMGDF on pharmacokinetics, megakaryocytopoiesis, platelet production, and platelet function were characterized for dosing 0.05, 0.10, 0.50, or 2.5 pglkgld in 22 baboons for 28 days. Daily subcutaneous injections of PEG-rHuMGDF produced linear logdose responses in (1) steady-state trough plasma levels of PEG-HuMGDF ( P < lo-?; (2) marrow megakaryocyte volume ( P < ploidy (P < lo-'), and number ( P < .Ol); and (3) peripheral platelet concentrations (P < 10-9 and platelet mass turnover (P < Platelet morphology, life span, and recovery were normal, and peripheral leukocyte, neutrophil, and erythrocyte counts were not significantly affected by PEG-rHuMGDF (P >
Thrombopoietin (TPO) is the physiologic Mpl-ligand regulating platelet production. Pegylated human recombinant megakaryocyte growth and development factor (PEGrHuMGDF), a truncated polypeptide Mpl-ligand derivitized with poly4ethylene glycol), induces megakaryocyte endoreduplication and proliferation in vitro and in vivo. In the present study, the dose-response effects of PEG-rHuMGDF on pharmacokinetics, megakaryocytopoiesis, platelet production, and platelet function were characterized for dosing 0.05, 0.10, 0.50, or 2.5 pglkgld in 22 baboons for 28 days. Daily subcutaneous injections of PEG-rHuMGDF produced linear logdose responses in (1) steady-state trough plasma levels of PEG-HuMGDF ( P < lo-?; (2) marrow megakaryocyte volume ( P < ploidy (P < lo-'), and number ( P < .Ol); and (3) peripheral platelet concentrations (P < 10-9 and platelet mass turnover (P < Platelet morphology, life span, and recovery were normal, and peripheral leukocyte, neutrophil, and erythrocyte counts were not significantly affected by PEG-rHuMGDF (P > .1 in all cases). PEGrHuMGDF at 0.5 pglkgld produced similar blood concentrations of Mpl-ligand and platelets as 10 times the dose of rHu-MGDF (5.0 pg/kg/dl, reflecting the extended plasma half-life achieved through pegylation. Whereas PEG-rHuMGDF did LATELET PRODUCTION is physiologically modu-P lated to compensate for changing peripheral requirements.'-6 The production of platelets is increased by inducing hematopoietic stem cell differentiation into the megakaryocyte lineage3.7-9 and stimulating the proliferation of megakaryocytes and their endoproliferative thereby amplifying the cytoplasmic substrate destined for fragmentation and release as functional circulating platelets."-'3 Thrombopoietin (TPO) is the physiologic Mpl-ligand stimulating megakaryocyte formation and endoreduplication. I 4 -' ' TPO levels in patients with thrombocytopenia after marrow ablative chemotherapy show reciprocal elevations and subsequent decline after restoration of the peripheral platelet count by platelet transfusions or recovery of marrow function.21. 22 Human megakaryocyte growth and development factor (~Hu-MGDF)~'.'~ is a recombinant nonglycosylated polypeptide encompassing the aminoterminal sequence of TPO structurally resembling erythr~poietin.~'.~~ In nonhuman primates, rHu-MGDF-stimulated megakaryocytopoiesis reproduces the features of thrombocytopenia-stimulated megakaryo~ytopoiesis.'~~'~ Because derivitizing rHu-MGDF with poly-(ethylene glycol) delays its clearance from plasma (Dr E. Cheung, unpublished observations), clinically relevant effects may be achieved with pegylated rHu-MGDF (PEGrHuMGDF) using substantially reduced dosing than that required for nonpegylated rHu-MGDF. In this report, we describe dose-response effects of PEG-rHuMGDF on platelet production and function in baboons and compare the findings with the results using nonpegylated rHu-MGDF.
MATERIALS AND METHODS
Twenty-two juvenile male baboons (Papio anubis) weighing 13 to 15 kg were used for this study.*' The animals Animals studied.
not induce platelet aggregation in vitro, platelet aggregatory responsiveness induced by thrombin receptor agonist peptide (TRAP1.@) and collagen was transiently enhanced ex vivo during the initial few days of PEG-rHuMGDF administration. However, adenosine diphosphate (ADPI-induced platelet aggregation was not enhanced ex vivo by PEG-rHuMGDF therapy. "'In-platelet deposition on segments of homologous endarterectomized aorta (EA) and vascular graft (VG) interposed in arteriovenous femoral shunts increased in direct proportion to the circulating platelet concentration ( P < lo-'
for both EA and VG); '%fibrin accumulation was not affected by PEG-rHuMGDF-induced increases in peripheral platelet counts. Changes in platelet production and function produced by PEG-rHuMGDF returned to baseline within 2 weeks after discontinuing treatment. Thus, in nonhuman primates, PEG-rHuMGDF increases platelet production in a linear log-dose-dependent manner by stimulating megakaryocyte endoreduplication and new megakaryocyte formation from marrow hematopoietic progenitors. These findings suggest that appropriate dosing of PEG-rHuMGDF therapy during periods of chemotherapy-induced marrow suppression may maintain hemostatic concentrations of peripheral platelets without increasing the risk of thrombosis. 0 1996 by The American Society of Hematology.
were quarantined, tested for tuberculosis, and observed to be diseasefree for 3 months before use. All procedures were approved by the Institutional Animal Care and Use Committee and conducted in accordance with federal guidelines (Guide for the Care and Use of Laboratory Animals. National Institutes of Health, Bethesda, MD, NIH Publication No. 86-23). For surgical procedures, animals received ketamine hydrochloride (20 mgkg intramuscularly) for induction, isoflurane and oxygen by endotracheal tube for anesthetic maintenance, and buprenorphine (0.01 mgkg every 8 hours as needed) postoperatively for pain management. Routine blood pressure and electrocardiographic monitoring was performed throughout the procedure and immediate postoperative period. Ketamine hydrochloride (5 to 20 m a g intramuscularly) was administered to achieve short-term immobilization for obtaining blood samples, bone marrow aspirates and biopsies, and scintillation-camera imaging.
After obtaining baseline measurements of platelet production and function, PEG-rHuMGDF at 0.05, 0.10, 0.50, and 2.50 pgkgld was administered by subcutaneous injection to four groups of 4 to 5 baboons each for 28 days while repeating the measurements of platelet production and function during the 4 weeks of PEG-rHuMGDF administration. Pharmacokinetic studies were performed in four additional animals.
Peripheral platelet counts, mean platelet volumes, red blood cell (RBC) counts, and total white blood cell (WBC) counts were determined in whole blood collected every other day in Na,EDTA (2 mg/mL) using a Serono/Baker model 9000 whole blood analyzer (Allentown,
The absolute neutrophil counts (ANCs) were ascertained manually from WBC differential counts on Wright-Giemsa-stained peripheral blood films. The baseline platelet count was 361 ? 14 x 103/pL, the RBC count was 4.75 t 0.40 X 106/pL, the leukocyte count was 13.5 2 2.9 x 103/pL, and the ANC was 3.8 2 1.1 x 103/pL. Routine chemistry profiles were obtained before and at the end of PEG-rHuMGDF treatment.
rHu-MGDF is a nonglycosylated polypeptide produced in Escherichia coli transfected with a plasmid containing cDNA that encodes for a region encompassing the erythropoietinlike aminoterminus of human TPO."." After extraction, refolding, and purification, this truncated protein was derivitized with poly-(ethylene glycol) (PEG-rHuMGDF) and further purified. The resulting pegylated monomeric molecular species was formulated in an aqueous buffer, sterilized by filtration, and provided as a gift from Amgen Inc (Thousand Oaks, CA). Endotoxin levels in the final product were less than 2.5 EUlmL. Dosing was based on protein weight.
Plasma levels of rHu-MGDF and PEG-rHuMGDF were determined using antibody-sandwich enzymelinked immunosorbant assays (ELISAs). The assay system used a polyclonal antibody raised in rabbits against recombinant human MGDF as the capture antibody. The same antibody conjugated to horseradish peroxidase (HRP) was used as the signal antibody. The sensitivity of the assay was 30 pg/mL.
Measurements of plateletfunction. Template bleeding time measurements were performed on the shaved volar surface of the forearm; baseline values averaged 3.8 2 0.9
Platelet aggregation was determined within 1 hour of drawing the blood using a Chrono-Log aggregometer (Havertown, PA) by recording the increase in light transmission through a stirred suspension of platelet-rich plasma (PRP) maintained at 37°C. PRP and platelet-poor plasma were prepared by differential centrifugation, as previously d e s~r i b e d .~~~~~
The platelet count in the PRP was adjusted to 300 X lo3 pL. ADP (Sigma, St Louis, MO), Horm collagen (Nycomed Arzenmittel, Munich, Germany), and TRAP,., (Peninsula Labs, Belmont, CA) were added at doses spanning the range of responsiveness. The results were plotted and expressed as the the agonist concentration that induced half-maximal aggregation (AC50). '8-3n The appearance of activated platelets in the peripheral blood was evaluated by flow cytometry using fluoresceinated monoclonal antibodies (MoAbs) against neoantigens expressed on membrane surfaces of activated platelets, including conformationally altered glycoprotein (GP) IIbnIIa, ligand-induced binding sites (LIBS; a gift from Dr E. Plow, Cleveland and the secretory granule membrane, P-selectin (a gift from Biogen Inc, Cambridge, MA)."." In addition, enhanced binding to platelets by fluoresceinated Annexin V (a gift from Dr T. Yokoyama, Tokyo, Japan) was also examined using flow ~ytometry.'~.~~ Annexin V, a member of the multigene family of calcium-dependent phospholipid binding proteins, exhibits high affinity for phosphatidylserine-rich negatively charged phospholipid platelet membrane binding sites promoting assembly of the macromolecular coagulation enzyme complexes."~"" Flow cytometric platelet studies were performed on blood collected in one-tenth volume 3.8% sodium citrate. PRP was obtained by differential centrifuLaboratory procedures.
MGDF reagents.
Plasma levels of Mpl-ligands. gation; 5 pL PRP was diluted to 50 pL in phosphate-buffered saline (PBS), pH 7.4, containing saturating concentrations of fluoresceinated marker protein and 1% bovine serum albumin (BSA) and incubated at 22°C. Annexin V was diluted in HEPES buffer (0.01 mol/L) in 0.15 m o m sodium chloride and 2.5 mmol/L calcium chloride and 1% BSA, pH 7.4. After 30 minutes of incubation with the appropriate antibody or binding protein and buffer, the platelets were diluted 10-fold with the incubation buffer without albumin and placed on ice until analyzed by flow cytometry. The findings were standardized each day against calibrated fluorescent beads (Flow Cytometry Standards Corp, San Juan, Puerto Rico).
Megakaryocyte number, size, and ploidy were measured by flow cytometry using a previously reported method for multiparameter correlative marrow analysis with a single-argon-ion-laser FACScan analyzer (Becton Dickinson, San Jose CA).10.41-4s Cell DNA in aspirated marrow was stained with propidium iodide, and surface membrane receptors were analyzed with antibodies labeled with fluorescein and phycoerythrin. Megakaryocytes expressing GPIIb/IIIa were enumerated in relation to the nucleated erythroid precursors expressing glycophorin A.4'.4h Measurements of megakaryocyte diameters were based on the time-offlight principle, ie, time required for a cell in suspension to pass through a focused light b e a~n . '~" ' .~' .~~ Aspirated bone marrow (3 mL) obtained from the pelvic bones was collected into IO-mL plastic syringes containing one-tenth volume acid-citrate-dextrose (ACD formula A), 2.5 mmoVL EDTA, and 2.2 pmol/L prostaglandin E, (PGE,; Sigma) final concentrations. The marrow was gently pipetted, passed through a 120-pm monofilament nylon filter, and diluted with cold Cazt-and Mg2'-free PBS containing 13.6 mmol/L sodium citrate, 2.2 pmol/L PGE, , 1 mmolL theophylline (Sigma), 3% BSA fraction V (Calbiochem, La Jolla, CA), 11 mmol/L glucose; the mixture was then adjusted to a pH of 7.3 and an osmolarity of 290 mOsm/L. Megakaryocytes were analyzed in marrow aspirates fractionated with 1.06 density Percoll (Pharmacia Biotech lnc, Piscataway, NJ). The nucleated erythroid marrow cells were analyzed from marrow separated over 1.08 density Percoll (Pharmacia Biotech Inc). Megakaryocytes were selected on the basis of their distinct immunofluorescence at levels above that of control cells labeled with an unrelated MoAb. In each sample, 2,000 to 3,000 megakaryocytes were analyzed. Bone marrow aspirates were obtained at baseline and after 3, 7, 14, and 28 days of PEG-rHuMGDF treatment.
Estimates of marrow megakaryocyte mass were used to represent the marrow substrate giving rise to circulating platelets and were calculated as the product of megakaryocyte numbers and mean megakaryocyte volume^."^^^* Normal baboon marrow values (n = 10) averaged a megakaryocyte diameter of 39 pm (range, 21 pm for 2 N to 56 pm for 64 N cells), a volume of 29.3 i-3.5 X IO3 fL, and a megakaryocyte number of 5.43 ? 2.6 X IO'kg, giving a total megakaryocyte mass of 16.2 I 8.4 X 10" fwkg. The normal modal ploidy was 16 N. Marrow biopsies were obtained from the proximal femur before and 4 weeks after beginning PEG-rHuMGDF therapy. The biopsies were processed for paraffin sectioning and stained for morphologic evaluation by light microscopy.
Steady-state platelet mass turnover (platelet concentration multiplied by mean platelet volume and divided by platelet life span and by recovery of injected labeled platelets) was used to estimate the rate at which viable platelet mass was delivered to the peripheral bl0od.4~ To measure platelet survival time, autologous platelets were labeled with "'In-oxine using the method described previously.jy Labeling efficiencies averaged 90%, and the labeled platelets functioned normally.'~sn After reinjection, daily blood samples were collected and analyzed for "'In-platelet activity to determine the rate at which "'In-platelets were cleared from the circulation. Platelet survival time, ie, the average time in circulation, was then calculated using computer least-squares fitting of the raw data to a gammaMeasurements of platelet production.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From function modeling program.49 The platelet survival time in normal baboons (n = 10) is 130 2 12 hours. The recovery of labeled platelets in the circulation at equilibrium was estimated by extrapolating the survival curve to time 0 and estimating the blood volume (70 mL/ kg) using the formula: Recovery in Circulation = Total Circulating Platelet RadioactivitylTotal Platelet Radioactivity Injected. Platelet recovery in normal baboons (n = 10) is 85% ? 4%.
To determine the effects of PEG-rHuMGDF-mediated increases in platelet production and function on the recruitment of platelets into vascular thrombi, we measured "'In-platelet and Iz5I-fibrin accumulation on thrombogenic segments of endarterectomized homologous aorta and Dacron vascular grafts. Surgically implanted exteriorized femoral arteriovenous (AV) Scribner-type access shunts were used for interposing thrombogenic segments and blood AV shunts of this design do not detectably shorten platelet survival times or fibrinogen removal rates and do not produce measurable activation of platelets or fibrin~gen.".~' Thrombogenic segments were subsequently interposed between the arms of the permanent shunt system of awake animals for 1 hour while measuring flow through the shunt using a C-clamp type flow probe interfaced with a Transonic T206 Blood Flow Analyzer (Transonic Corp, Ithaca, NY). Blood flows were maintained at 100 " i n .
Thrombus accumulation onto these surfaces was measured with a gamma camera as radiolabeled platelet accumulation over time. 52.53 Fresh baboon aorta (5 to 6 mm internal diameter [ID]) was obtained from other donor animals, flushed with saline, and divided into 4-cm lengths. Branches were ligated and specimens were stored in normal saline. Endarterectomies were performed by everting the aortic segments and removing the intima and inner media for a distance of 1 cm in the central portion of the vessel using sharp dissection. After completion of the endarterectomy, each segment was retumed to its normal configuration and cannulated using 1-cm lengths of heat-shrinkable Teflon tubing (Small Parts, Inc, Miami, FL) attached to segments of 4 mm ID silicone rubber medical tubing (Dow Coming, Inc, Coming, NY). The aortic segments were encased with heat-shrinkable Teflon tubing, sealing each end carefully by heating, but avoiding direct heat to the tissues. The resultant configuration maintained stable geometry with a smooth transition from vessel to tubing. For imaging, the entire apparatus was connected to additional lengths of 3-mm silicone rubber tubing and incorporated into the A-V shunt system with 2-cm-long tapered Teflon connectors (Small Parts, I~c ) . '~.~~ Segments of knitted Dacron vascular graft (4 mm ID; Bioknit) were obtained from C.R. Bard, Inc (Billerica, MA). Segments 2 cm in length were rendered impervious to blood leakage by external wrapping in Parafilm (American Can Co, New York, NY) and 5.3 mm ID heat shrink Teflon tubing. Butt joints were constructed that ensured smooth luminal flow surface^.^^.^^.^^ For the platelet imaging procedures, autologous baboon platelets were labeled with 1 mCi "'Indium ("'In) oxine, as previously des~r i b e d , S~-~~ and reinjected at least l hour before imaging. Total deposited "'In-platelet activity was determined at endarterectomy sites or on the segments of vascular graft using region-of-interest analysis. Images were acquired continuously for 60 minutes in 5-minute intervals using a GE 400T scintillation camera (General Electric, Milwaukee, WI). The data were stored and analyzed on a Medical Data System A3 Computer (Medasys Inc, Ann Arbor, MI). A medium-energy collimator was placed close to the animal. Total platelet deposition, including both labeled and unlabeled platelets, was calculated by dividing the deposited "'In-platelet activity by circulating "'In-platelet activity (blood standard) and multiplying by the circulating platelet count (platelets per milliliter of whole blood) as measured in the blood standard sample. The results were expressed as the total deposited platelets. Radioactivity values in Measurements of thrombus formation.
these calculations refer to platelet activity only, with blood and standard values corrected for the small fraction of nonplatelet "'Inactivity.
Homologous '251-fibrinogen (5 p a ) , prepared by a method described previously?'-53 was injected at least 15 minutes before initiating thrombosis studies. The '251-fibrinogen was shown to be 95% clottable and functionally equivalent to unlabeled fibrinogen. Thrombogenic segments were obtained at the conclusion of each study, washed, and stored for 30 days until the "'In activity had decayed. Then, the incorporated '251-radioactivity was measured by gamma counter. Deposited fibrin (in milligrams) was calculated by dividing the '251-a~tivity (in counts per minute [cpm]) in each segment by the coagulable plasma '251-a~tivity (in cpm per milliliter) and multiplying by the plasma fibrinogen level (in milligrams per milliliter).52.53 Results were expressed as the total accumulated fibrin (in milligrams per centemeter). The concentration of fibrinogen in plasma was estimated spectrophotometrically by a modification of Jacobsson's method.56
Baseline control platelet and fibrin deposition onto segments of endarterectomized aorta and Dacron vascular graft were determined and repeat measurements were obtained after 1 and 4 weeks of PEGrHuMGDF treatment.
For ultrastructural examination of platelets, 5 mL of blood was drawn into one-tenth volume 3.8% sodium citrate anticoagulant. After removing erythrocytes and leukocytes by differential centrifugation, an equal volume of 0.1% glutaraldehyde in pH 7.4 PBS was added and platelets were pelleted at room temperature by centrifugation at 800g for 5 minutes. The supernatant was decanted, and 3% glutaraldehyde in PBS, pH 7.4, was layered over the pellet for 1 hour and then processed for transmission electron microscopy. For megakaryocyte morphology, the pelleting was performed at 180s for 5 minutes at 4"C.57 Marrow cores were obtained using clinical techniques, fixed in 10% buffered formalin solution, embedded in paraffin, sectioned, and stained with polychromatophilic dyes for examination at the light level.
Data were analyzed using SIGMA STAT (Jandel Scientific Software, San Rafael, CA). Comparisons between two groups were performed using the two-tailed Student's t-test, unless the data were not distributed randomly, in which case nonparametric analysis was performed. Analysis of variance (ANOVA) was used to compare values for a particular group at various time points?' Unless otherwise stated, variance about the mean is given as 2 1 SD.
Morphology.
Data analysis.

RESULTS
PEG-rHuMGDF pharmacokinetics.
The subcutaneous daily injection of 0.05, 0.10, 0.50, and 2.50 pg/kg/d PEGrHuMGDF produced dose-dependent increases in steadystate plasma trough levels (Fig 1) . Average trough levels were calculated from predose concentrations obtained after 4 days of dosing. Plasma concentrations from the 0.05 pg/ kg dose level were below the detection limits of the assay. Steady-state trough concentrations for the 0.10, 0.50, and 2.50 pg/kg/d dose levels were 0.03 5 0.01, 0.26 t 0.13, and 1.52 ? 0.5 1 ng/mL, respectively. Area under the plasma concentration versus time curves (t-AUC,.,) from the four animals receiving 0.5 pg/kg/d was calculated using trapezoidal methods. Ratio of the AUC on days 4 to 1 was 2.65 t 0.88, indicating approximately twofold to threefold accumulation after daily dosing of PEG-rHuMGDF. Steady state was attained by day 4. After administration of the first dose, peak plasma concentration was observed at greater or equal to 6 hours, except for 1 animal that reached the peak 4
For hours after dosing. The terminal half-life (Tsop) for PEGrHuMGDF in 3 of the 4 animals ranged from 10 to 28 hours. One baboon showed an exceptionally large value of 75 hours. Because this was inconsistent with attaining steady state by day 4 in this animal, the half-life was considered to be an outlier over-estimate. The T,, averaged 21.5 t 10 hours (excluding the outlier). The peripheral platelet counts were not acutely altered by the initial subcutaneous injection of PEG-rHuMGDF (data not shown; P = .34).
The concentration of circulating platelets increased incrementally in a dose-dependent manner, attaining peak values 2 weeks after initiating PEG-rHuMGDF injections (Fig 2; P < in all cases). For the 50-fold dose range examined in this study, the maximum increases in platelet counts produced by PEG-rHuMGDF were directly related to the logarithm of the administered dose (Fig 3; r = .94 ). Platelet ultrastructure (data not shown) and platelet lifespan were normal, ie, 130 t 14 hours ( P = .68 compared with baseline value of 130 t 12 hours).
The mean platelet volume (MPV) decreased as the platelet count increased, ie, at the 0.5 pg/kg/d dose MPV decreased by about 20% (8.0 t 1.2 v 6.6 t 0.8 fL,; P < .01; Table 1 ).
However, there was no correlation between the change in MPV and the dose of PEG-rHuMGDF administered ( Table  1 ; P = .5 by ANOVA).
After discontinuing therapy, platelet counts decreased to baseline values and MPVs normalized within 2 weeks (Fig  2) . Peripheral leukocyte, neutrophil, or erythrocyte counts did not change significantly during PEG-rHuMGDF administration (P > . 1 in all cases, comparing basal and weekly values during therapy).
Platelet mass turnover, a steady-state measure of the rate at which platelet mass enters the peripheral circulation, increased in a log-linear dose-response manner (Fig 3 and Table 1 dosing rHu-MGDF 5 pg/kg/d; P = .3).26 Thus, the 10-fold increased effect resulting from pegylating rHu-MGDF was largely attributable to delayed clearance and prolonged plasma half-life of PEG-rHuMGDF compared with nonpegylated rHu-MGDF. PEGrHuMGDF increased megakaryocyte number, size, and ploidy in a log-linear dose-dependent fashion ( Fig 5 and Table 2 ; r = .97 for volume and r = .98 for ploidy). Basal measurements were compared with findings obtained after 3 and 14 days of PEG-rHuMGDF treatment ( Table 2) .
Mean megakaryocyte volumes were increased by PEGrHuMGDF therapy, attaining maximum increases by day 3 ( Table 2 ). The increase in megakaryocyte volumes produced by PEG-rHuMGDF was directly related to the logarithm of the dose administered (Fig 5A; r = .99) . Similarly, megakaryocyte ploidy was directly related to the logarithm of the dose admnistered (Fig 5A; r = .98) . Modal ploidy values increased from the normal of 16 N to 32 N, with reciprocal decreases in the 2 N to 16 N cohorts (Fig 6; P < .01 in all cases). Megakaryocyte volume and ploidy remained increased throughout the period of therapy ( Table 2 and In determining marrow megakaryocyte numbers, the ratio of marrow megakaryocytes to marrow nucleated erythroid forms was measured by relating nucleated GPIIb/IIIa-positive cells to nucleated glycophorin A-positive nucleated erythroid cells using MoAbs to GPIIb/lIIa and erythroid-specific glycophorin, respectively, together with supravital nuclear staining. The ratio of megakaryocytes to nucleated erythroid forms was then multiplied by the estimated total number of marrow nucleated erythroid precursors in normal baboons (assumed to be 5.3 X lo9 erythroid cellskg, based on ferrokinetic studies in
The basal megakaryocyte:erythroid ratio was 1.62 ? 0.26 X yielding basal megakaryocyte numbers of 5.4 5 2.6 X lo6 megakaryocytes/ kg.46,48*59 PEG-rHuMGDF produced log-linear dose-response expansion of the number of marrow megakaryocytes ( Fig   5B and Table 2 ; r = .92). For example, the 0.5 pg/kg/d dose increased the megakaryocyte number twofold by day 7 (17.2 2 10.4 X lo6 megakaryocyteskg), and fourfold by day 28 (31.8 2 22.0 X lo6 megakaryocyteskg; P < .OOOl).
Total megakaryocytopoiesis was estimated as marrow megakaryocytes mass, which represented the product of the total number of megakaryocytes and their mean ~o l u m e~'~~* The resultant megakaryocyte mass increased in a log doseresponse fashion (Fig 5B; r = .95) . For example, 0.5 pgkgl d dosing increased megakaryocyte mass sixfold to 99 ? 9.9 X 10" fLkg by day 14 (Table 2; P < .OW1 compared with basal values), corresponding to a sixfold increase in platelet mass ( Fig 5B and Table 2 ). Effects of PEG-rHuMGDF on platelet function. Escalating concentrations of circulating platelets induced by PEGrHuMGDF enhanced platelet hemostatic function, as shown by the shortening of template bleeding time measurements within the first few days of therapy (Table 3 ; P < .01).
Because bleeding time determinations are relatively insensitive to enhanced hemostatic reactivity, platelet function was then evaluated independent of changes in peripheral platelet counts by assessing ex vivo responsiveness to physiologic agonists in PRP from animals receiving PEG-rHuMGDF (with platelet counts normalized to 300 X 103/pL) and by measuring the expression of platelet activation epitopes.
Ex vivo platelet aggregatory responsiveness to ADP was not significantly altered after administering the initial or subsequent doses of PEG-rHuMGDF (Fig 7 and Table 3 ; P > .lo). However, PEG-rHuMGDF transiently enhanced platelet aggregation induced by TRAP,., and collagen during the initial few days of therapy (Fig 7 and Table 3 ; P < .05 in both cases ), ie, the concentration of collagen inducing halfmaximal aggregation decreased significantly, from 2.8 ? 1.9 to 1.1 2 0.9 pg/mL ( P = .03); for the concentration 83 to 17 2 15 pmol/L ( P < .001). These effects were blocked by 100 pg/mL soluble Mpl-receptor (Fig 8) . No significant augmentation of platelet aggregation ex vivo was observed after day 7 despite continuation of PEG-rHuMGDF therapy (Fig 7 and Table 3 ).
To investigate the effects of PEG-rHuMGDF on platelet function, in vitro aggregation studies were also performed using platelets obtained from normal untreated animals and humans. In vitro, no platelet aggregation was induced by concentrations of PEG-rHuMGDF ranging from 1 ng/mL to 1000 ng/mL (Fig 8; P > S) . However, in vitro aggregatory responses by baboon platelets to low-dose ADP (4.9 pmol/ L) and collagen (1.5 pg/mL) were enhanced twofold by 10 ng/mL PEG-rHuMGDF (Fig 8A; P < .05 in both cases), effects that were blocked by IO-fold excess soluble Mplreceptor (Fig 8A) . Similar PEG-rHuMGDF-dependent enhancement of platelet aggregatory responses in vitro and blockade by excess soluble Mpl receptor were observed for human platelets using ADP and collagen, albeit at concentrations of 2.2 pmol/L ADP, 0.3 pg/mL collagen, and 1 0 0 ng/ mL PEG-rHuMGDF to achieve maximal enhancing effects (Fig 8B) .
The possibility that PEG-rHuMGDF might inherently activate platelets was also investigated by flow cytometric assessment of epitopes known to be expressed during platelet activation, ie, binding of MoAbs detecting the conformational change in GPIIb/lIIa that mediates fibrinogen receptor function (LIBS) and the emergence of platelet secretory granule membrane protein (P-selectin) on platelet surfaces. The binding of fluorescein-labeled Annexin V to phosphatidylserine-rich activated platelet membranes was also evaluated using flow cytometry. There was no increase induced by PEG-rHuMGDF for any of these platelet markers of activation ex vivo or in vitro. The average number of LIBS epitopes on resting unstimulated platelets decreased significantly (Table 3 ; P = .004).
Effects of PEG-rHuMCDF on thrombosis. The possibility that PEG-rHuMGDF might amplify thrombus formation was examined by comparing basal versus treatment measurements of "'In-platelet deposition and '*'I-fibrin accumulation on segments of homologous endarterectomized aorta (EA) and vascular graft (VG) interposed in arteriovenous femoral shunts in baboons. Platelet accumulation into thrombus forming on these thrombogenic segments was proportional to the elevation in peripheral platelet count early in the study, between days 5 and 7 when platelet counts were increasing and ex vivo platelet aggregation was enhanced, and 3 weeks later when platelet counts were steady-state and platelet responsiveness was normal, ie, platelet deposition was 4.4 f 1.3 versus 12 2 2 X lo9 platelets on VG (Fig 9A; P < .0001) and 1.8 2 0.1 versus 10 5 2 X lo9 platelets on EA (Fig 9B; 
DISCUSSION
The present findings show that injecting PEG-rHuMGDF subcutaneously into baboons at doses ranging between 0.05 and 2.5 pg/kg/d selectively amplifies megakaryocytopoiesis and platelet production in a log-linear dose-dependent manner by inducing early megakaryocyte endoreduplication and subsequent progressive expansion in megakaryocyte formation from marrow progenitor cells. PEG-rHuMGDF exhibits lineage-dominant megakaryocytopoietic activity that is approximately 10-fold greater than nonpegylated rHu-MGDF because pegylation prolongs plasma half-life. The wave of newly formed platelets elevating the peripheral platelet count exhibits normal morphology, reciprocal reduction in mean platelet volume, and early transient enhancement of platelet aggregatory responsiveness to and collagen ex vivo. However, platelet deposition onto thrombogenic segments under arterial flow conditions is proportional to the circulating concentration of platelets, without any enhancement in thrombogenesis attributable to enhanced platelet responsiveness during the early period when daily subcutaneous PEG-rHuMGDF augments platelet aggregation induced ex vivo by or collagen.
PEG-rHuMGDF has no effect on the concentration of peripheral platelets during the first 3 days of treatment, showing that the final processes of megakaryocyte cytoplasmic maturation and delivery into the circulation are independent of Mpl ligands. The initial increases in peripheral platelet counts reflect platelets arising from pre-existing megakaryocytes undergoing, on average, one additional endoreduplicative event with a corresponding doubling in megakaryocyte volumes, followed by progressive increases in marrow megakaryocyte numbers (Table 2) . Because ploidy changes occur early (by day 3), are log-linear dose-dependent, and are readily measured by flow cytometry, megakaryocyte ploidy is a very useful early quantitative indicator of stimulation by Mpl ligand^."^^'^^ The rate at which peripheral platelet counts decrease after discontinuing PEG-rHuMGDF injections ( Figs 2 and 4) represents the summation effects of the 5-to 6-day platelet lifespan, together with the continuing release of platelets from the cytoplasm of already matured marrow megakaryocytes. Overall, the results of this study show that Mpl ligand-dependent thrombocytopoiesis is largely effective and capable of increasing platelet production at least 10-fold over basal levels.
As the concentration of circulating platelets increases in response to PEG-rHuMGDF, the mean platelet volume decreases, returning to normal only after PEG-rHuMGDF injections are stopped (Fig 4 and Table 1 ). This reciprocal relationship between platelet volume and peripheral platelet count has been observed previously in experimental animals and in human^^^.".^^ and is associated with stimulated megakaryocytopoiesis during experimental thrombocytopenia induced by mechanical platelet removal in nonhuman primates."@ The inverse relationship between platelet volume and peripheral platelet count has been interpreted to mean that circulating platelet mass (the product of platelet volume and concentration) is a more meaningful determinant of the competition exhibited by circulating platelets for unbound Mpl ligands than the platelet count alone. By contrast, stimulated megakaryocytopoiesis is associated with larger platelets in rodents when thrombocytopenia is produced by antiplatelet antib~dies.'~.'' Although the mechanism underlying the production of smaller platelets in the present study is not known, it is characteristic of secondary thrombocytosis in humans and may simply reflect incomplete expansion of accumulating cytoplasm when Mpl ligands potently stimulate endoreduplication.
The present results show that injections of 0.5 pg/kg/d PEG-rHuMGDF produce similar circulating levels of Mpl ligand and comparable increases in megakaryocytopoiesis and platelet production as was achieved using 10-fold greater dosing of rHu-MGDF (Tables 1 and 2 Mpl receptors on circulating platelets compete for unbound TPO in plasma. Accordingly, platelet mass (the product of platelet concentration and platelet volume) is inversely related to the circulating physiologic level of unbound endogenous Mpl-ligand.60 Because TPO knockout mice show no translational regulation of Mpl-ligand produ~tion,~' competition for endogenous plasma Mpl ligand by receptor-bearing platelets and megakaryocytes, as well as soluble Mpl receptor in plasma, may represent the principal physiologic feedback mechanism regulating platelet production. The intensity of megakaryocytopoietic responses to PEGrHuMGDF is determined by the plasma levels of unbound For personal use only. on September 24, 2017. by guest www.bloodjournal.org From PEG-rHuMGDF (Figs 1 and 3) . Because the circulating levels of exogenous PEG-rHuMGDF exceed physiologic TPO levels by several orders of magnitude, they are largely unaffected by competitive binding with even the fivefold elevation in the circulating platelet mass.
With the wave of newly formed platelets appearing in the circulation after day 3 and before day 7 after PEGrHuMGDF therapy, ex vivo platelet aggregatory responses to and collagen are transiently enhanced (Fig 7 and  Table 3 ). Because this heightened responsiveness is blocked by excess Mpl receptor in vitro (Fig 8) , the increased sensitivity is not due to artifacts of PRP preparation or contamination of the PEG-rHuMGDF preparation or other reagents. In vitro, PEG-rHuMGDF alone does not directly induce platelet aggregation at concentrations ranging from 1 ng/mL to 1,000 ng/mL (Fig 8).68,69 However, PEG-rHuMGDF at concentrations of 10 to 100 ng/mL augment in vitro aggregatory responses to minimal doses of physiologic agonists (Fig 8) , an effect that is abolished by excess soluble Mpl receptor (Fig 8) , implying that the mechanism involves some interreceptor reinforcement pathway. As opposed to the enhancing effects of rHu-MGDF on ADP-induced platelet aggregation ex vivo,26 PEG-rHuMGDF fails to augment platelet aggregatory responsiveness to ADP ex vivo (Fig 7) . The relevance of the ex vivo findings for pathophysiologic processes remains uncertain, because the evidence for transient platelet hyperresponsiveness is based on finding increased aggregatory responses ex vivo without corresponding expression of activation epitopes by circulating platelets ( Table 3 ) and without direct physiologic evidence for enhanced platelet deposition onto thrombogenic surfaces independent of the elevated peripheral platelet mass per se.
Evaluation of the thrombotic consequences associated with the administration of PEG-rHuMGDF is of potential clinical relevance because older cancer patients undergoing chemotherapy may be at risk of developing thrombo-occlusive complications due to their underlying malignancy in association with atherosclerotic vascular disease. In measuring the effects of PEG-rHuMGDF on thrombus formation, the relative accumulation of "'In-platelets and Iz5I-fibrin was determined in thrombus forming on segments of two wellcharacterized thrombogenic surfaces, endarterectomized homologous aorta and knitted prosthetic vascular graft. These thrombogenic segments are interposed in arteriovenous shunts for fixed periods under standard flow conditions without systemic anticoagulati~n.~~.~~ These models are highly reproducible and well-suited for repeated comparisons. The number of deposited platelets in normal baboons is directly related to the peripheral platelet count (Fig 9) . 36 In the present study, a direct linear relationship between platelet deposition and platelet count extending over the range of 350 to 2,200 X 1@/pL in animals receiving PEG-rHuMGDF. These models show that thrombus formation does not exceed that predicted by the peripheral platelet concentration, indicating that the in vitro and ex vivo evidence of enhanced platelet responsiveness is not translated into increased thrombus formation in vivo. Similarly, rHu-MGDF receptor has been reported to have no enhancing effect on thromboembolic cyclic flow reductions in a rabbit model of carotid stenosis, despite enhancement of ADP-induced aggregation ex v~v o .~" Because PEG-rHuMGDF reproduces the selective alterations in megakaryocytes and platelet mass turnover characteristic of physiologic regulation'-335 and toxicity is not detectable in the nonprimate model described here, PEG-rHuMGDF may be suitable for clinical application in patients exhibiting transfusion-dependent thrombocytopenia or other thrombocytopenic disorders responsive to exogenous stimulation of platelet production. Because thrombotic complications are related to the magnitude to which platelet counts surpass normal levels, appropriate dosing of PEGrHuMGDF after marrow suppressive chemotherapy should prevent thrombocytopenia without increasing the risks of platelet-dependent thrombosis.
